$STLN 8-K SEC Filings

Filed On	Filing
02 Sep 2026	8-K: Departure/Election of Directors or Officers; Compensation
21 Aug 2026	8-K: Entry into a Material Definitive Agreement; Creation of a Direct Financial Obligation
06 Aug 2026	8-K: Results of Operations and Financial Condition CERRITOS, Calif., August 6, 2026 -- Starling Oncology, Inc. (NASDAQ: STLN) (“STLN” or the “Company”), one of the largest value-based community oncology groups in the United States, today reported financial results for its quarter ended J...
03 Aug 2026	8-K: Amendments to Articles/Bylaws; Change in Fiscal Year; Regulation FD Disclosure
07 Jul 2026	8-K: Entry into a Material Definitive Agreement; Creation of a Direct Financial Obligation +2 more
18 Jun 2026	8-K: Submission of Matters to a Vote of Security Holders
22 May 2026	8-K: Material Cybersecurity Incidents
07 May 2026	8-K: Results of Operations and Financial Condition
13 Mar 2026	8-K: Regulation FD Disclosure
12 Mar 2026	8-K: Results of Operations and Financial Condition
23 Feb 2026	8-K: Departure/Election of Directors or Officers; Compensation; Regulation FD Disclosure
12 Jan 2026	8-K: Results of Operations and Financial Condition
07 Jan 2026	8-K: Departure/Election of Directors or Officers; Compensation; Regulation FD Disclosure
01 Dec 2025	8-K: Departure/Election of Directors or Officers; Compensation; Regulation FD Disclosure
14 Nov 2025	8-K: Regulation FD Disclosure
13 Nov 2025	8-K: Results of Operations and Financial Condition
06 Nov 2025	8-K: Regulation FD Disclosure
13 Aug 2025	8-K: Results of Operations and Financial Condition
13 Aug 2025	8-K: Departure/Election of Directors or Officers; Compensation; Regulation FD Disclosure
19 May 2025	8-K: Regulation FD Disclosure

Comments